Beranda › Kanker Darah › Massachusetts › Boston
Uji klinis Kanker Darah di Boston, MA
25 studi untuk Kanker Darah mencari peserta di lokasi sekitar Boston (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Menerima pesertaFase 1/2
- Dana Farber Cancer Institute, Boston
Multidisciplinary Intervention for Adults With Chronic Graft-versus-host Disease
Menerima peserta
- Massachusetts General Hospital, Boston
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Menerima pesertaFase 1
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
Menerima pesertaStudi observasional
- Brigham and Women's Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
SURGE: Supporting Utility and Representation in Genomics-based Cancer Trial Enrollment (Intervention)
Menerima peserta
- Dana Farber Cancer Institute, Boston
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Menerima pesertaFase 2
- Dana-Farber Cancer Institute, Boston
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Menerima pesertaFase 1/2
- Massachusetts General Hospital, Boston
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Menerima pesertaFase 1
- Beth Israel Deaconess Medical Center, Boston
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- Dana Farber Cancer Institute, Boston
PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
Menerima pesertaFase 2
- Brigham and Women's Hospital, Boston
Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)
Menerima pesertaSukarelawan sehat diterima
- Dana-Farber Cancer Institute, Boston
Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies
Menerima pesertaFase 3
- Tufts Medical Center, Boston
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Menerima pesertaStudi observasional
- Tufts Medical Center, Boston
- Beth Israel Deaconess, Boston
- Dana Farber Cancer Institute, Boston
IVIG for Infection Prevention After CAR-T-Cell Therapy
Menerima pesertaFase 2
- Massachusetts General Hospital Cancer Center, Boston
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Menerima pesertaStudi observasional
- Dana-Farber Cancer Institute, Boston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Menerima pesertaFase 1
- Dana Farber Cancer Institute, Boston
Feasibility and Acceptability of Primary Palliative Care Intervention in Patients Undergoing Hematopoietic Stem Cell Transplantation
Menerima peserta
- Massachusetts General Hospital, Boston
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
Menerima peserta
- Massachusetts General Hospital Cancer Center, Boston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Menerima pesertaFase 1/2
- Dana Farber Cancer Institute, Boston
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Menerima pesertaFase 1
- Massachusetts General Hospital, Boston
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
Menerima pesertaFase 1/2
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
BMT-CARE: Psychosocial Intervention for Transplant Caregivers
Menerima peserta
- Massachusetts General Hospital Cancer Center, Boston
HEME Home Transfusion Program
Menerima peserta
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Menerima pesertaFase 1
- Dana-Farber Cancer Institute, Boston
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Menerima pesertaFase 1
- Dana-Farber Cancer Institute, Boston
Uji klinis Kanker Darah di kota lain
- Houston, TX46 studi
- New York City, NY26 studi
- Washington, DC19 studi
- Baltimore, MD18 studi
- Seattle, WA18 studi
- Los Angeles, CA17 studi
- Durham, NC16 studi
- Chicago, IL15 studi
- Philadelphia, PA14 studi
- Atlanta, GA13 studi
- Nashville, TN13 studi
- Edison, NJ13 studi
Studi lain di Boston
- Kanker Payudara111 studi
- Kanker Paru Non-Sel Kecil90 studi
- Kanker (semua jenis)86 studi
- Kanker Kolorektal63 studi
- Kanker Metastatik63 studi
- Kanker Paru62 studi
- Kanker Ovarium61 studi
- Kanker Prostat59 studi
- Depresi52 studi
- Kanker Endometrium50 studi
- Gagal Jantung44 studi
- Leukemia Mieloid Akut44 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.